On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight ...
Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results